Study of Bulevirtide in Participants With Chronic Hepatitis D Infection

November 14, 2025 updated by: Gilead Sciences

A Registry Study of Treatment With Bulevirtide in Participants With Chronic Hepatitis D Infection

The main goal of this study is to collect post marketing data from patients with chronic hepatitis D virus (HDV) infection who are treated with bulevirtide to describe the long-term effects of bulevirtide treatment and evaluate the safety of participants treated with bulevirtide.

Study Overview

Status

Active, not recruiting

Conditions

Intervention / Treatment

Detailed Description

The study design time perspective is retrospective and prospective for participants who previously participated in MYR-Reg-02 and are currently receiving BLV and prospective for participants who are scheduled to receive BLV.

Study Type

Observational

Enrollment (Actual)

170

Expanded Access

Available outside the clinical trial. See expanded access record.

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Austria
      • Graz, Austria, A-8036
        • Medizinische Universität Graz Universitätsklinik für Innere Medizin, Klinische Abteilung für Gastroenterologie und Hepatologie
      • Hall in Tirol, Austria, 6060
        • Aö Landeskrankenhaus Hall
      • Innsbruck, Austria, 6020
        • Universitätsklinik für Innere Medizin I Innsbruck
      • Vienna, Austria, 1090
        • Medizinische Universitat Wien
  • France
      • Angers, France, 49933
        • Centre Hospitalier Universitaire d'Angers
      • Bobigny, France, 93000
        • Hôpital Avicenne - APHP
      • Clichy, France, 92118
        • Hôpital Beaujon
      • Créteil, France, 94010
        • Hôpitaux Universitaires Henri Mondor
      • Grenoble, France, 38043
        • Chu Grenoble Alpes
      • Lille, France, 59037
        • Centre Hospitalier Universitaire De Lille- Hôpital Huriez
      • Limoges, France, 87042
        • Chu de Limoges - Hopital Dupuytren
      • Lyon, France, 69317
        • Hôpital de la Croix-Rousse
      • Montpellier, France, 34295
        • Hôpital Saint Eloit
      • Paris, France, 75013
        • APHP Hôpital Pitié Salpêtrière
      • Pessac, France, 33604
        • Hôpital Haut-Lévêque
      • Pringy, France, 74374
        • Centre Hospitalier Annecy Genevois
      • Périgueux, France, 24019
        • Centre Hospitalier de Perigueux
      • Rennes, France, 35033
        • CHU Rennes - Hopital Pontchaillou
      • Rouen, France, 76000
        • Hôpital Charles-Nicolle - CHU de Rouen
      • Toulouse, France, 31060
        • Hôpital Rangueil - CHU de Toulouse
  • Germany
      • Berlin, Germany, 10961
        • Leber- und Studienzentrum Checkpoint
      • Berlin, Germany, 13353
        • Charité. Univeritätsmedizin Berlin, CMM & CVK, Department of Hepatology and Gastroenterology
      • Bonn, Germany, 53127
        • Universitätsklinikum Bonn, Medizinische Klinik und Poliklinik I
      • Düsseldorf, Germany, 40225
        • Universitätsklinikum Düsseldorf, Klinik für Gastroenterologie, Hepatologie und Infektiologie
      • Essen, Germany, 45147
        • Universitätsklinikum Essen
      • Frankfurt, Germany, 60590
        • Universitätsklinikum Frankfurt Goethe-Universität
      • Giessen, Germany, 35392
        • Universitätsklinikum Gießen und Marburg - Gießen, Medizinisch Klinik V
      • Hamburg, Germany, 20099
        • IFI- Institut für interdisziplinäre Medizin
      • Hanover, Germany, 30625
        • Medizinische Hochschule Hannover
      • Kiel, Germany, 24105
        • Liver Study Centre Kiel
      • Munich, Germany, 81675
        • Klinikum Rechts Der Isar Der Technischen Universität München
      • Wiesbaden, Germany, 65189
        • St Josephs-Hospital Wiesbaden, Med Klinik 2
  • Romania
      • Bucharest, Romania, 050098
        • Spitalul Universitar de Urgenta Bucuresti
      • Bucharest, Romania, 22328
        • Fundeni Clinical Institute
      • Bucharest, Romania
        • Fundeni Clinical Institute
      • Bucharest, Romania, 030303
        • Dr. Victor Babes Clinical Hospital for Infectious and Tropical Diseases
      • Bucharest, Romania, 11356
        • Prof. Dr. Agrippa Ionescu Emergency Clinical Hospital
      • Bucharest, Romania, 21105
        • National Institute of Infectious Diseases "Prof. Dr. Matei Balş"
      • Craiova, Romania, 200349
        • Spitalul Clinic Judetean De Urgenta Craiova
      • Iași, Romania, 700111
        • Gastromedica Srl
      • Iași, Romania, 700116
        • Hospital for Infectious Diseases St. Cuvioasa Paraschiva
      • Timișoara, Romania
        • Clinical Hospital for Infectious Diseases and Pneumophthisiology Dr. Victor Babe
      • Timișoara, Romania
        • Emergency County Clinical Hospital "Pius Brînzeu" Timişoara
  • Spain
      • Almería, Spain, 04009
        • Complejo Hospitalario Torrecárdena
      • Barcelona, Spain, 08036
        • Hospital Clinic De Barcelona
      • Barcelona, Spain, 08035
        • Hospital Universitari Vall d'Hebron
      • Córdoba, Spain, 14004
        • Hospital Universitario Reina Sofia
      • Madrid, Spain, 28222
        • Hospital Universitario Puerta de Hierro - Majadahonda
      • Madrid, Spain, 28029
        • Hospital Universitario La Paz. Paseo de la Castellana 261
      • Santa Cruz de Tenerife, Spain, 38010
        • Hospital Universitario Nuestra Señora de Candelaria
  • United Kingdom
      • London, United Kingdom, NW3 2QG
        • Royal Free London NHS Foundation Trust
      • London, United Kingdom, SE5 9RS
        • King's College Hospital NHS Foundation Trust
      • London, United Kingdom, E1 1FR
        • Barts Health NHS Trust

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

This study will enroll participants who participated in Study MYR-Reg-02 or are scheduled to receive BLV according to the approved product label and not currently enrolled in a clinical treatment study.

Description

Key Inclusion Criteria:

  • Individuals who have been diagnosed with chronic hepatitis D virus (HDV) infection for at least 6 months before study enrollment, confirmed by respective documentation in the individuals' medical records.
  • Must have the ability to understand and sign a written informed consent form, which must be obtained prior to initiation of study procedures.
  • Must be willing and able to comply with the visit schedule and study requirements.
  • Cohort 1 only: Must have participated in study MYR-Reg-02.
  • Cohort 2 only: Individuals scheduled to receive bulevirtide (BLV) according to the approved label or for whom the decision to start treatment with BLV according to the approved label has been made and treatment initiation is planned.

Key Exclusion Criteria:

  • Individuals currently enrolled in BLV clinical treatment studies and/or other interventional clinical studies with an investigational agent.
  • History or current presence of clinically significant illness or any other major medical disorder that may interfere with individual follow-up, assessments, or compliance with the protocol.
  • Coinfection with hepatitis C virus (HCV) or human immunodeficiency virus (HIV) (Individuals with HCV antibodies can be enrolled if HCV RNA is negative).
  • Solid organ transplantation.
  • Any history, or current evidence of clinical hepatic decompensation (ie, ascites, encephalopathy, jaundice, or gastrointestinal bleeding (GIB)).
  • Presence of hepatocellular carcinoma (HCC) as evidenced by imaging (eg, ultrasound or computed tomography scan) performed within 4 months prior to Day 1 for individuals with cirrhosis and within 6 months prior to Day 1 for individuals without cirrhosis.
  • Pregnant or breastfeeding females.
  • Individuals with a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection confirmed by a positive polymerase chain reaction test result.
  • Known hypersensitivity or contraindication to BLV or formulation excipients.
  • Individuals who are committed to an institution by virtue of a court or official order.
  • Individuals deemed by the study investigator to be inappropriate for study participation for any reason not otherwise listed. This includes persons dependent on the sponsor, investigator, or trial site.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Bulevirtide (previously participated in Study MYR-Reg-2)
Participants who are currently receiving bulevirtide (BLV) according to the approved label and have participated in Study MYR-Reg-02.
Drug: Bulevirtide
Administered via subcutaneous (SC) injections
Other Names:
  • Hepcludex®
Bulevirtide
Participants who are scheduled to receive BLV according to the approved label.
Drug: Bulevirtide
Administered via subcutaneous (SC) injections
Other Names:
  • Hepcludex®

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Exposure-adjusted Incidence of Participants With Liver-related Event: Hepatic Decompensation, Hepatocellular Carcinoma (HCC), Liver Transplantation, and Liver-related Death
Time Frame: Up to 144 weeks
Up to 144 weeks

Secondary Outcome Measures

Outcome Measure
Time Frame
Percentage of Participants Who Develop Cirrhosis During The Study Among Participants Who Were Previously Noncirrhotic
Time Frame: Up to 144 weeks
Up to 144 weeks
Percentage of Participants With Serious Adverse Events
Time Frame: First dose date up to 144 weeks plus 30 days
First dose date up to 144 weeks plus 30 days
Percentage of Participants With Grade 3 or 4 Adverse Events (AEs)
Time Frame: First dose date up to 144 weeks plus 30 days
First dose date up to 144 weeks plus 30 days
Percentage of Participants With Discontinuations Due to AEs
Time Frame: First dose date up to 144 weeks plus 30 days
First dose date up to 144 weeks plus 30 days

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Gilead Sciences

Investigators

  • Study Director: Gilead Study Director, Gilead Sciences

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

February 7, 2023

Primary Completion (Estimated)

July 1, 2028

Study Completion (Estimated)

July 1, 2028

Study Registration Dates

First Submitted

January 30, 2023

First Submitted That Met QC Criteria

January 30, 2023

First Posted (Actual)

February 8, 2023

Study Record Updates

Last Update Posted (Actual)

November 17, 2025

Last Update Submitted That Met QC Criteria

November 14, 2025

Last Verified

November 1, 2025

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • GS-US-589-6206
  • 2022-501901-10 (Other Identifier: European Medicines Agency)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Chronic Hepatitis D Infection

Clinical Trials on Bulevirtide

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Algeria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe